tbuckley/cabot-search huggingface dataset:
Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.
Authors: Michael Crump, Sattva Swarup Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Mohamed Amin Ahmed, Brian K. Link, Annette E. Hay, James Robert Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew John Maurer, Lynn Navale, Jeffrey S. Wiezorek, William Y. Go, Christian Gisselbrecht
Journal: Journal of Clinical Oncology (2016)

7516 Background: Patients with relapsed/refractory DLBCL have heterogeneous outcomes to subsequent therapy. The subgroup of these patients with refractory disease (r-DLBCL) have a worse prognosis. A multi-cohort study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research) was performed to evaluate outcomes for patients with r-DLBCL and serve as a benchmark for future clinical trials in this population. Methods: Eligible subjects had r-DLBCL defined as progressive disease (PD) or stable disease (SD) as best response to chemotherapy (duration of SD <12 mos and at least 4 cycles of first-line or 2 cycles of later line therapy) or relapse ≤12 mos of ASCT. Patients must have received an anti-CD20 monoclonal antibody (unless CD20-) and an anthracycline as one of their prior regimens. Data from 2 phase 3 studies (LYSARC-CORAL and Canadian Cancer Trials Group-LY.12), and 2 observational cohorts (MD Anderson Cancer Center (MDACC), and Mayo Clinic / University of Iowa (MC/IA) Specialized Program of Research Excellence) were integrated. Response rate (RR) and overall survival (OS) were estimated from start of salvage therapy. Results: Data for 861 patients with DLBCL were available for analysis and 597 patients with r-DLBCL were identified, with subgroups and outcomes shown in the table. An integrated analysis of outcomes will be presented. Conclusions: In this large multi-center dataset, patients with r-DLBCL have homogenous outcomes with a response rate of 20%-30% and median overall survival of approximately 6 mos. This consistently poor outcome represents a significant unmet medical need. MDACC (n=152) MC / IA (n =84) CCTG LY.12 (n=190) CORAL (n=171) Median agea (range) 55 (20, 79) 61 (20, 84) 54 (25, 68) 54 (19, 65) RR (%) 19 23 24 36 CR 7 8 2 18 PR 13 14 23 18 RR by subgroup (%) Primary refractory (n=142) NA 28 24 NA Refractory to > 2nd line therapy (n=306) 19 26 NA 36 Relapse < 1 year post ASCT (n=149) 21 11 NA 35 Median OS (Q1, Q3) - mos 6.9 (5.8, 8.2) 4.6 (3.9, 5.8) 6.8 (5.8, 8.2) 6.7 (5.6, 8.8) aCORAL included subjects 18 – 65, Ly.12 studies included subjects ≥ 16; subjects > 65 were not recommended for inclusion. NA – due to study design.
Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease
Authors: G.B. John Mancini, Michael E. Farkouh, Maria M. Brooks, Bernard R. Chaitman, William E. Boden, Helen Vlachos, Pamela M. Hartigan, Flora S. Siami, Mandeep S. Sidhu, Vera Bittner, Robert Frye, Valentin Fuster
Journal: Journal of the American College of Cardiology (2016)
Responsiveness Of Cytogenetically Discrete Human Myeloma Cell Lines To Lenalidomide: Lack Of Correlation With Cereblon and Interferon Regulatory Factor 4 Expression Levels
Authors: Alexandra J Greenberg, Denise K Walters, Bonnie Kaye Arendt, Renee C. Tschumper, Shaji K. Kumar, S. Vincent Rajkumar, Diane F. Jelinek
Journal: Blood (2013)
Selective Activation of Anticancer Chemotherapy by Cancer-Associated Fibroblasts in the Tumor Microenvironment
Authors: Mi-Gyeong Kim, Yuna Shon, Jinyoung Kim, Yu-Kyoung Oh
Journal: JNCI Journal of the National Cancer Institute (2016)

The tumor microenvironment has recently emerged as a new target of anticancer chemotherapy. Selective activation of anticancer chemotherapy in the tumor microenvironment would further reduce the toxicity of anticancer drugs toward normal tissues. Fibroblast activation protein (FAP) is known to be selectively overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Here, we designed an anticancer chemotherapeutic system based on promelittin, a peptide toxin that is selectively converted from an inactive form to the pore-forming melittin upon cleavage by FAP in the tumor microenvironment.We conjugated promelittin-containing FAP-cleavable sequences to pegylated phospholipids and anchored them to reduced graphene oxide (rGO) nanosheets. The resulting nanosheets, PL-rGO, were tested for hemolysis and used for doxorubicin delivery. In vitro cocultures and in vivo tumor growth (n = 5 mice per group) with tissue immunostaining were used to test the selective activation of anticancer chemotherapy by FAP expressed on CAFs.FAP-specific hemolytic activity of PL-rGO was observed in cocultures of CAFs and HT29 cells but not in HT29 cells alone. Doxorubicin-loaded PL-rGO (Dox/PL-rGO) showed 3.4-fold greater cell-killing efficacy (compared with free Dox in the CAF/HT29 coculture system, effects that were not observed in HT29 cells alone). Intravenously administered Dox/PL-rGO reduced the growth of HT29 tumors more effectively than other treatments (Dox/PL-rGO: mean = 200.6 mm(3), 95% confidence interval [CI] = 148.7 to 252.5 mm(3); free Dox: mean = 697.0 mm(3), 95% CI = 646.9 to 747.1 mm(3), PL: mean = 565.0 mm(3), 95% CI = 550.5 to 579.6 mm(3); Dox/rGO: mean = 637.6 mm(3), 95% CI = 619.5 to 655.7 mm(3); PL-rGO: mean = 464.4 mm(3), 95% CI = 433.0 to 495.8 mm(3)). Immunostaining of tumor tissues revealed that survival of CAFs and HT29 cells was lowest in the group treated with Dox/PL-rGO.The demonstration of selective activation of PL-rGO by FAP on CAFs suggests that PL-rGO may serve as a tumor microenvironment-responsive anticancer chemotherapy system.
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement—Reply
Authors: Michael Mack
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL
Authors: Long Xuan Trinh, Young Kwang Chae, Preetesh Jain, Ohad Benjamini, Xuemei Wang, Susan Lerner, William G. Wierda, Zeev Estrov, Michael J. Keating
Journal: Blood (2012)
Caring for the Poor
Authors: Leo Uzych
Journal: JAMA (1988)

To the Editor.—  The impassioned diatribe of Dr Weaver 1 concerning health care for the poor warrants, I believe, further comment.  There is a stereotyped view held by some members of the public that some physicians practice clinical medicine in an uncaring, insensitive manner. I believe the nature of the comments made by Dr Weaver may function to kindle the flames of such a stereotype. In fact, Dr Weaver's comments may constitute a veritable textbook example of medical arrogance.  Dr Weaver professes disgust with the editorial by Dr Lundberg and Mr Bodine 2 and the article by Dr Hilfiker. 3 But, ironically, Dr Weaver's letter may engender the same type of unpleasant emotion. At least in my view, to generalize about poor persons as being bums, or dregs of humanity, who supposedly procreate prolifically and illegitimately and are hopeless and useless is patently crude, distasteful, and offensive. Dr Weaver's forthrightly
Discovery Research On the Effects of Continuous Administration of Bortezomib Maintenance Therapy to Treat Patients with Relapsed and Refractory Multiple Myeloma - Analysis of Background Factors That Affect the Continuity of Therapy-
Authors: Kenshi Suzuki, Nobuhiro Tsukada, Yu Abe, Rieko Sekine, Yasunori Nakagawa
Journal: Blood (2012)
The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure–Lowering Trials
Authors: Salim Yusuf, Eva Lonn
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF)
Authors: Maria Delores Pastor, Ana Nogal, Sonia Molina-Pinelo, Álvaro Quintanal-Villalonga, Ricardo Meléndez, I. Ferrer, Beatrice Romero-Romero, Maria José De Miguel, José Luis López-Campos, Jesús Corral, Rocío García-Carboner, Amancio Carnero, Luis Paz-Ares
Journal: Journal of Thoracic Oncology (2016)
S48 Inefficient ventriculo-arterial coupling contributes to reduced exercise capacity in pulmonary hypertension: Abstract S48 Table 1.
Authors: C McCabe, None Hoole, P White, R Axell, L Shapiro, J Pepke-Zaba
Journal: Thorax (2013)

<h3>Introduction</h3> Ventriculo-arterial (VA) coupling (Ees/Ea) in the right heart is defined by RV end-systolic elastance (Ees) and pulmonary arterial effective elastance (Ea) with Ees/Ea representing the mechanical efficiency of forward flow from the RV. Ees/Ea may influence exercise capacity in pulmonary hypertension (PH) because patients exhibit cardiac limitation at peak oxygen uptake (peak VO<sub>2</sub>) and suffer impaired exercise cardiac output adaptation. We hypothesised that Ees/Ea in the RV represents a physiological index of myocardial reserve and thus at inefficient ratios, may predispose to reduced exercise capacity. <h3>Methods</h3> Using RV conductance catheterisation and contemporaneous incremental cardiopulmonary exercise testing, we evaluated Ees/Ea against peak VO<sub>2</sub> in twenty patients with pulmonary vascular disease. Ees/Ea was compared with haemodynamic predictors of exercise capacity obtained from standard right heart catheterisation. <h3>Results</h3> Resting Ees/Ea, absolute peak VO<sub>2</sub> and predicted peak VO<sub>2</sub> were 0.86 ± 0.40, 19.6 ± 6.7ml/Kg/min and 88 ± 23% respectively. Univariable predictors of absolute peak VO<sub>2</sub> were patient gender, NYHA class, mean right atrial pressure, mean pulmonary artery pressure, cardiac index, conductance RV stroke volume and Ees/Ea (all p &lt; 0.10). On bivariate analysis, the predictive value of Ees/Ea improved following adjustment for RV stroke volume (p = 0.03) but not for mean RA pressure (p = 0.21). Only Ees/Ea related linearly to percent predicted VO<sub>2</sub> (R<sup>2</sup> = 0.32, p = 0.01). RV diastolic decay (-dP/dt<sub>min </sub>)showed good correlation with O<sub>2</sub> pulse evolution (r = 0.62, p &lt; 0.01) although no single haemodynamic parameter differentiated absolute peak VO<sub>2</sub> above and below its median value. <h3>Discussion</h3> VA coupling is a marker of RV energetic efficiency and adds to the debate on the multifactorial determinants of exercise capacity in PH. Ees/Ea was comparable to other predictive haemodynamic parameters of exercise capacity and may represent the ‘recruitable’ myocardial reserve, important for maintaining cardiac output at increased metabolic demand. Ees/Ea may be a potential therapeutic target given the unclear relationship between pulmonary haemodynamics and patient symptoms.
More Rapid Delivery of Parenteral Analgesia By Adding Intranasal Fentanyl to the Management of Sickle Cell Disease Vaso-Occlusive Pain Episodes at a Pediatric Emergency Department
Authors: Bolanle T Akinsola, Robert Hagbom, April Zmitrovich, Patricia Kavanagh, Ashley Ashkouti, Amy Fletcher, Natalie Vinson, Harold Simon, Alesia Fleming, Shabnam Jain, Olufolake Adisa, Carlton Dampier, Claudia R. Morris
Journal: Blood (2014)
Лікувальна тактика при кістозних утвореннях підшлункової залози залежно від їх походження, активності запалення та характеру ускладнень
Authors: V.M. Ratchik, N.V. Prolom, O.M. Babii, D.V. Orlovskyi, H.V. Tuzko
Journal: GASTROENTEROLOGY (2016)

У відділенні хірургії органів травлення ДУ «Інститут гастроентерології НАМН України» за 2011–2015 роки спостерігалися 472 пацієнти з патологічними змінами підшлункової залози. Хірургічне лікування проведене у 87 пацієнтів із кістозними утвореннями підшлункової залози. Залежно від походження та зрілості кіст, стану протокової системи та активності запалення паренхіми підшлункової залози оперативні втручання були розподілені на чотири типи: І — дренуючі (виконано у 52 (59,8 %) пацієнтів); ІІ — цист­ектомічні (4; 4,6 %); ІІІ — резекційно-дренуючі (11; 12,6 %) та ІV — резекційні (14; 16,1 %) операції. Непрямі види оперативних втручань виконано у 6 (6,9 %) пацієнтів. Післяопераційні ускладнення відзначено у 16 (18,3 %) випадках. Летальний кінець був в одному випадку (1,2 %).
MLL-Rearranged Acute Myeloid Leukemias Drive Expression Of Mir-9, a Critical Oncogene In Leukemogenesis
Authors: Colles Price, Ping Chen, Zejuan Li, Yuanyuan Li, Anissa Wiley, Chunjiang He, Rejani B. Kunjamma, Hao Huang, Xi Jiang, Stephen Arnovitz, Mary Beth Neilly, Janet D. Rowley, Jianjun Chen
Journal: Blood (2013)
Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias.
Authors: Yusuke Ono, Hidenori Karasaki, Koji Imai, Junpei Sasajima, Shin-ichi Chiba, Hiroshi Funakoshi, Miho Muraki, Hideki Hanaoka, Takahisa Furukawa, Hiroyuki Furukawa, Toru Kono, Kazuo Nagashima, Yusuke Mizukami
Journal: Journal of Clinical Oncology (2015)

330 Background: Clonal populations originated from benign-looking “founder cells” may spread widely within pancreas instead of being localized in situ before frank pancreatic ductal adenocarcinoma (PDA) can be detected. Metachronous PDA is not common event, and we here sought to define potent origin of multiple PDAs developed in a woman by using advanced genetics technologies. Methods: In addition to precise pathological assessment, genetic approaches such as deep sequencing of multiplex PCR amplicons of cancer-associated genes (Ion Torrent PGM platform) and digital PCR were employed. Results: Curative resection of pancreatic head tumor was performed; however, “recurrent” lesions in the remnant pancreas were found 3.5-years later and total pancreatectomy was subsequently performed. The metachronous lesions were morphologically similar to the primary PDA. All 3 PDAs were shown to possess rare somatic mutations in KRAS (p.T58I and p.Q61H). Curiously, identical KRAS mutations were found in low-grade “intraepithelial” lesions, which localized in normal area of the pancreas and one of them possessed p53mutation, which was also found in the PDAs. Conclusions: Rare KRAS haplotype was identified in the metachronous PDAs in the current case. Surprisingly, the identical somatic mutations were also found in independent low-grade “intraepithelial” lesions with and without additional mutation in p53. The footprint of the tumor evolution marked by mutational profiling supports a human correlate to the mouse models of “dissemination” occurring at the earliest stages of pancreatic neoplasia.
Prostacyclin modifies VEGF synthesis in fibroblasts from healthy and COPD patients
Authors: Anna-Karin Larsson, Oskar Hallgren, Leif Bjermer, Claes-Göran Löfdahl, Gunilla Westergren-Thorsson
Journal: European Respiratory Journal (2011)

Background: Involvement of vascular remodelling in the lung is a characteristic sign in chronic obstructive lung disease (COPD). The vascular mediator prostacyclin may regulate fibroblast activity. The objective was to study the effect of prostacyclin on synthesis of vascular endothelial growth factor (VEGF) and interactions with transforming growth factor (TGF) B1 in distal lung fibroblasts from patients with COPD and control subjects.

Method: Primary human lung fibroblast cultures were established from peripheral airway biopsy samples from healthy individuals (controls, n=5) and after lung resection from patients with COPD (GOLD IV) (n=7). The lung fibroblasts were cultured in 0.4% medium and stimulated with the cyclooxygenase inhibitor indomethacin 3μM in combination with the prostacyclin analogue iloprost 1μM and TGF-B 10ng/ml for 24h. VEGF production was measured in the cell culture supernatant by ELISA.

Results: Iloprost enhanced VEGF synthesis in both fibroblasts from control subjects (774±171 vs 438±55 pg/ml, p<0.05) and patients with COPD (350±34 vs 512±81 pg/ml, p<0.05). TGF-B increased the production of VEGF 5-fold in fibroblasts from control subjects (p<0.05) and 6.1-fold from patients with COPD (p<0.01). However, iloprost showed no effect on VEGF synthesis after TGF-B stimulation, whereas indomethacin reduced VEGF production in fibroblasts from patients with COPD (p<0.05) but not in control subjects.

Conclusions: Iloprost enhanced VEGF synthesis in fibroblasts from both healthy and patients with COPD. Though, iloprost had no effect on VEGF after TGF-B1 stimulation. This data implicate that also other prostanoids are involved in the regulation of VEGF in fibroblasts from COPD patients.
Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy.
Authors: R. Karmali, M. J. Fidler, I. Cela, G. Olmsted, O. Rouhi, S. Basu, K. K. Walters, J. Coon, P. Bonomi, J. A. Borgia
Journal: Journal of Clinical Oncology (2010)

7553 Background: The insulin growth factor receptor-1 (IGFR-1) signaling pathway is implicated in the oncogenesis of NSCLC and resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI). A recent prospective analysis found baseline low levels of IGF binding proteins (BP) were associated with superior survival in advanced NSCLC treated with erlotinib (Fidler et al. WCLC, 2009). This study measured the same in chemotherapy treated patients. Methods: Luminex-based immunoassays were used to measure circulating serum levels of IGFBP 1-7, prospectively collected in advanced NSCLC patients prior to starting chemotherapy. Disease progression was measured using RECIST criteria when imaging was available. Data was analyzed using Mann-Whitney two sided rank sum test and log rank in SPSS v15.0. Results: 74 patients were enrolled. The median age was 65. 36 were women, 46 had adenocarcinoma, 12 were never smokers. 58 received first line chemotherapy, 13 - second line, 3 - ≥ third line. Median OS was 10.2 months with 21 patients alive at the end of study. Low serum IGFBP-2 (< 15 ng/mL) was associated with prolonged median OS compared with high levels (13.4 vs 8.3 months, p < 0.05); similarly, low levels of IGFBP-4 (< 90 ng/mL) correlated with prolonged median OS of 12.8 vs 2.0 months with high levels (p < 0.05). Low serum IGFBP-7 (< 81 ng/mL) corresponded with improved median PFS compared with high levels (5.6 vs 2.8 months, p < 0.05). Conclusions: Our previous observations with IGFBP's in NSCLC patients on EGFR-TKI's and now in chemotherapy treated patients suggest IGFR signaling pathway mediated through IGFBPs might be a common mechanism of resistance. Combining IGFR-1 inhibitors with cytotoxics or EGFR- TKI's might be more efficacious in patients with high serum IGFBP's and requires further validation. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abbott Laboratories, Genentech, Lilly Abbott Laboratories
Long-Term Prognostic Utility of Coronary CT Angiography in Stable Patients With Diabetes Mellitus
Authors: Philipp Blanke, Christopher Naoum, Amir Ahmadi, Chaitu Cheruvu, Jeanette Soon, Chesnal Arepalli, Heidi Gransar, Stephan Achenbach, Daniel S. Berman, Matthew J. Budoff, Tracy Q. Callister, Mouaz H. Al-Mallah, Filippo Cademartiri, Kavitha Chinnaiyan, Ronen Rubinshtein, Hugo Marquez, Augustin DeLago, Todd C. Villines, Martin Hadamitzky, Joerg Hausleiter, Leslee J. Shaw, Philipp A. Kaufmann, Ricardo C. Cury, Gudrun Feuchtner, Yong-Jin Kim, Erica Maffei, Gilbert Raff, Gianluca Pontone, Daniele Andreini, Hyuk-Jae Chang, Benjamin W. Chow, James Min, Jonathon Leipsic
Journal: JACC. Cardiovascular imaging (2016)
Safety of a Weekly Administration of 7.5 mg/kg of Liposomal Amphotericin B (LAB) for Antifungal Prophylaxis in Patients Receiving High Dose Corticosteroids (CS) for Acute GVHD after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).
Authors: Jean El-Cheikh, Catherine Faucher, Sabine Furst, Hugues de Lavallade, Didier Blaise, Mohamad Mohty
Journal: Blood (2005)